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Early Health Technology Assessment during
Nonalcoholic Steatohepatitis Drug
Development: A Two-Round, Cross-Country,
Multicriteria Decision Analysis
Aris Angelis , Mark Thursz, Vlad Ratziu, Alastair O’Brien,
Lawrence Serfaty, Ali Canbay, Ingolf Schiefke, Joao Bana e Costa,
Pascal Lecomte, and Panos Kanavos
Background. The assessment of value along the clinical development of new biopharmaceutical compounds is a chal-
lenging task. Complex and uncertain evidence has to be analyzed, considering a multitude of value preferences from
different stakeholders. Objective. To investigate the use of multicriteria decision analysis (MCDA) to support deci-
sion making during drug development while considering payer and health technology assessment (HTA) value con-
cerns, by applying the Advance Value Framework in nonalcoholic steatohepatitis (NASH) and testing for the
consistency of the results. Design. A multiattribute value theory methodology was applied and 2 rounds of decision
conferences (DCs) were organized in 3 countries (England, France, and Germany), with the participation of national
key experts and stakeholders using the MACBETH questioning protocol and algorithm. A total of 51 health care
professionals, patient advocates, and methodologists, including (ex-) committee members or assessors from national
HTA bodies, participated in 6 DCs in the study countries. Target Population. NASH patients in fibrosis stages F2 to
3 were considered. Interventions. The value of a hypothetical product profile was assessed against 3 compounds
under development using their phase 2 results. Outcome Measures. DC participants’ value preferences were elicited
involving criteria selection, options scoring, and criteria weighting. Results. Highly consistent valuation rankings
were observed in all DCs, always favoring the same compound. Highly consistent rankings of criteria clusters were
observed, favoring therapeutic benefit criteria, followed by safety profile and innovation level criteria. Limitations.
There was a lack of comparative treatment effects, early evidence on surrogate endpoints was used, and stakeholder
representativeness was limited in some DCs. Conclusions. The use of MCDA is promising in supporting early HTA,
illustrating high consistency in results across countries and between study rounds.
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The assessment of value along the clinical development
and regulation of a new medicine is complex and involves
different decision problems. It commences with manufac-
turers’ internal decisions regarding which disease areas to
invest in as part of research and development (R&D)
portfolio prioritization and progresses to choices related to
clinical study design, regulatory assessment of the product’s
benefit-risk profile, payer evaluation of reimbursement
conditions via health technology assessment (HTA),
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and concludes with prescriber behavior based on clini-
cal guidance and individual patient need. Arguably, for
better decisions and improved transparency, the prefer-
ences of decision makers should more often be quanti-
fied and explicitly communicated.1
The early HTA context, in which payer concerns
relating to the expected value of new compounds are
explored before the licensing stage, is becoming more
important in Europe. This is reflected through the joint
work plan of the European Medicines Agency (EMA)
and the European Network for Health Technology
Assessment (EUnetHTA),2,3 an important aspect of
which is parallel consultation4 and EUnetHTA Early
Dialogue.5 Early HTA empirical studies are becoming
more frequent, and although a number of methods have
been used to identify and evaluate technologies, the use
of multicriteria decision analysis (MCDA) has been rec-
ommended as a tool to support decisions in product
development.6,7
Decision analysis methods and, specifically, quantita-
tive modeling approaches such as MCDA can be used to
aid medical decision making, to explicitly integrate
objective measurement with value judgment while man-
aging subjectivity transparently. This is useful for drug
evaluation contexts because, although the clinical evi-
dence concerning different treatments’ performance
might be objective in nature, the understanding of its
value requires subjective interpretation; for example,
relating to the relevance of data for the disease of inter-
est, the meaningfulness of improvement in health benefit,
and the value trade-offs with possible risks8.
A method of eliciting value preferences from different
stakeholder groups is decision conferencing,9,10 a form
of face-to-face workshops guided by a facilitator while
applying decision theory with multiple objectives.11 In
medical decision making, MCDA methods in combina-
tion with decision conferencing could be used as a tool
to elicit and communicate value preferences across a
number of evaluation aspects with the view to ranking a
set of alternative medical options based on their value.12
Since European drug regulators called for more expli-
cit and quantitative methodological approaches in the
assessment of drug benefit-risk balance with well-defined
evaluation criteria and the valuation of outcomes
through numerical weights,13 a number of MCDA stud-
ies have been conducted in the licensing context.14–16
The EMA currently adopts and recommends the use of
the ‘‘effects table’’ for the tabulation of the most impor-
tant favorable and unfavorable effects and their uncer-
tainty,17 a constituent step of MCDA methodologies18.
Other similar structured frameworks are also implemen-
ted by drug regulators for increasing transparency in the
communication of benefits and risks,19 including by the
US Food and Drug Administration.20
Due to various limitations of economic evaluation
methods, MCDA applications in the context of HTA
have intensified in recent years.21,22 Good practice guide-
lines for the use of MCDA and its adaptation to HTA
have been developed,23–25 and different multicriteria
value frameworks have been recommended.26–29 A num-
ber of empirical studies have been conducted, often simu-
lating different HTA settings30–33 or by involving and
eliciting the preferences of real decision makers and eva-
luators across different settings.34–37 Still, a number of
challenges relating to the appropriate use of such methods
and their integration with policy-making have been raised
that would be critical for MCDA implementation.38,39
Although MCDA approaches have been explored in
the context of product development and treatment selec-
tion, fewer studies exist compared with the drug approval
context. Relevant case studies include the use of MCDA
and decision conferencing to prioritize R&D project
portfolios of pharmaceutical companies and budget
allocation40 and the use of a stochastic MCDA
approach for the selection of statins in primary
prevention.41
In the context of early HTA, no quantitative, cross-
country MCDA studies exist. More broadly, in the con-
text of health care evaluation, there have been no
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validating MCDA studies testing the consistency of their
results by repeating the exercise with different groups of
participants.
In this study, we investigate the use of the Advance
Value Framework (AVF), a multicriteria value frame-
work,27 to assess the value of compounds in clinical devel-
opment for the treatment of nonalcoholic steatohepatitis
(NASH). A key objective is to test the consistency of the
results, both between and within countries, by conducting
2 rounds of decision conferences (DCs). An early-stage
HTA scope is adopted in an attempt to make the best use
of available evidence at the time of the study, with the col-
lection of views from key stakeholders across 3 countries
(England, France and Germany). Given the compounds’
early clinical development stage, a set of hypothetical
assumptions are imposed in some cases on their perfor-
mance for the purpose of enabling their comparative
assessment. The output generated aims to engage key
experts and decision makers in discussions around com-
pound value at this early stage in their development, to
communicate their value prospects while aligning with
increasing clinical evidence availability, rather than
inform clinical or policy decisions.
Methods
Methodological Framework and Overall Process
The AVF is based on multiattribute value theory
(MAVT)10,42 and comprises 5 distinct phases: a) problem
structuring, b) model building, c) model assessment, d)
model appraisal and e) development of action plans.25
The AVF was operationalized using a decision support
system (M-MACBETH) enabling the use of graphics to
build a model of values, acting as a facilitation tool to
inform both the structuring phases (‘‘a,’’ ‘‘b’’) and the
evaluation phases (‘‘c,’’ ‘‘d’’)43; the development of action
plans phase (‘‘e’’) was not conducted because of the early
development phase of the compounds.
The study consisted of 2 rounds. The first took place
between November 2016 and June 2017 and included all
4 phases (a–d) with the involvement of 26 participants in
3 DCs (1 in each country); the second took place between
November 2017 and June 2018, acting as a follow-up to
validate the results obtained in the first round by con-
ducting the 3 latter phases of the methodological process
(b–d) and involving 25 participants, the purpose being to
elicit additional preferences through 3 further DCs in the
same study countries. Both rounds used an identical
methodological approach in relation to value preference
elicitation and construction.
Following problem structuring (phase a), as part of
model building (phase b), an extensive review of the clini-
cal literature was conducted to understand the clinical
endpoints of interest and in consultation with a clinical
hepatologist, co-author of the study (M.T.), a prelimi-
nary version of a NASH value tree was developed along-
side the collection of the appropriate performance data,
which was validated at the beginning of each DC. During
model assessment (phase c) and model appraisal (phase
d), DC participant value preferences were elicited and
were used to inform, first, compound scoring against the
evaluation criteria and, second, criteria weighting. The
process was completed by analyzing the results, including
sensitivity analysis.
Phase a. Problem Structuring: Clinical
Practice and Scope
Nonalcoholic fatty liver disease (NAFLD) is the most
common chronic liver disease worldwide, affecting as
many as 30% of adults and 70% to 80% of those who
are obese and have type 2 diabetes.44 NAFLD represents
a histologic spectrum of conditions, ranging from simple
steatosis to NASH and cirrhosis. Many with simple stea-
tosis do not develop significant liver disease, however
NASH can progress to cirrhosis, hepatocellular carci-
noma and end-stage liver disease; it has become the sec-
ond leading aetiology of liver disease among adults
awaiting liver transplantation in the United States.45
NASH is projected to become the leading indication for
liver transplantation within the next decade (for more
clinical information see the Supplementary Appendix).
In the context of this study, a simulation exercise was
undertaken focusing on the assessment of the overall
value of compounds in clinical development for the treat-
ment of NASH, by adopting an early HTA perspective
focusing on market access and coverage decisions with
the involvement of key stakeholders, including HTA
experts and proxy decision makers.
Phase b. Model Building: The Advance Value
Tree Adaptation, Alternative Treatments and
Evidence, Attribute Ranges and References
1. The Advance Value Tree (AVT) adaptation for NASH
As part of the AVF, the AVT is a generic value tree pro-
viding HTA-related value concerns for new medicines in
a hierarchical structure of evaluation criteria.27 Based on
a structured process involving systematic review and
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expert consultation46 and adopting a top-down approach,47
the AVT consists of 5 value domains (i.e. criteria clusters),
capturing all essential value attributes of new medicines in
the HTA context under a prescriptive decision-aid
approach: 1) burden of disease (BoD), 2) therapeutic bene-
fit (THE), 3) safety profile (SAF), 4) innovation level
(INN), and 5) socioeconomic impact (SOC), such that
overall value is a function expressed as follows:
Value= f BoD,THE,SAF, INN,SOCð Þ ð1Þ
The latest available evidence from clinical studies was
used to populate the performance of the alternative
options across the respective criteria attributes of the
AVT. The AVT was thus adapted for the context of
NASH as part of a bottom-up, alternative-focused think-
ing approach, following the comparison of the alternative
compounds, in consultation with a hepatology specialist
(M.T., study co-author).25,48 This adaptation resulted in
the preliminary version of the NASH value tree, which
served as the basis of assessing the value of NASH com-
pounds in the first round of DCs, comprising a total of
17 criteria attributes. The burden of disease cluster was
removed because all alternative treatments were assessed
for the same indication, whereas socioeconomic impact
criteria were excluded because of lack of evidence.
Following the completion of the first round of DCs,
the final version of the value tree was used as the starting
point for the second round of DCs, that is, the prelimi-
nary version in the second part of the exercise. In arriv-
ing at the NASH-specific attributes and the respective
value tree, we strived to adhere to key decision theory
properties such as preferential independence and nonre-
dundancy, thus ensuring attribute selection was metho-
dologically correct and theoretically robust.49
2. Alternative treatments compared and evidence considered
A total of 4 compound profiles were assessed, 3 with
publicly available phase 2 results plus a hypothetical
product profile (HPP); the latter was viewed as an
‘‘aspirational summary’’ of a hypothetical product in
terms of labeling concepts, leveraging hypothetical infor-
mation about the compound available at a particular
time in development,50 effectively providing a prospective
summary of the characteristics of a product that could
theoretically be achieved.51 Information on the HPP was
communicated by the study sponsor. Because of the com-
mercial in confidence information surrounding the HPP,
all compounds are anonymized in the study.
Given the early assessment scope of the exercise with
no available drug treatment on the market for NASH,
we used the most relevant clinical evidence for the assess-
ment of the compounds, including a number of assump-
tions for the performance of the HPP. Expert opinion
was used to specify the performance of options across
specific criteria in case such information was not
available.
The final performance of options used across the dif-
ferent criteria attributes together with the respective
range of placebo arms and lower – higher (i.e., least pre-
ferred – most preferred) reference levels used in the mod-
els is shown in Supplementary Table A1; additional
information on evidence considered is discussed in the
Supplementary Appendix.
3. Setting attribute ranges and reference levels
For the purposes of scoring and weighting, ‘‘higher’’
(x_h, set at 100) and ‘‘lower’’( x_l, set at 0) reference lev-
els were defined for each attribute acting as benchmarks
of an interval value scale based on which the compounds
were scored, that is, v(xhigher) = 100 and v(xlower) = 0.
The ‘‘higher’’ reference corresponded to the best avail-
able performance on that attribute and the ‘‘lower’’ cor-
responded to the worst available performance across the
compounds compared. These reference levels were
needed for the construction of criteria partial value func-
tions on interval scales and the elicitation of relative
weights. Given the application of an additive aggregation
model, a hypothetical overall weighted preference value
(WPV) score of 100 for a compound would entail the
best possible performance across all criteria, whereas an
overall WPV score of 0 would entail the worst possible
performance across all criteria (see Appendix Table A1,
last 2 columns for worst and best reference levels of all
criteria).
Phase c. Model Assessment; and Phase d- Model
Appraisal: DCs and MCDA Technique
In each of the 2 DC rounds, the completion of model-
building, model assessment and part of the model apprai-
sal phases took place through 3 DC meetings with key
stakeholders, mimicking what would occur in the respec-
tive settings10; these took the form of facilitated work-
shops lasting 1 to 1.5-days each and were conducted in
England (London), France (Paris) and Germany (Berlin).
DC participants consisted of small groups of experts,
ranging between 5 and 13 participants. We endeavoured
to involve all relevant stakeholder groups and pers-
pectives, reflecting actual assessment processes in the
study countries; specifically, health care professionals,
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methodologists, and patient representatives were included.
These sizes have been shown to be optimal, allowing effi-
cient group processes to emerge while preserving indivi-
duality, as they are large enough to represent all major
perspectives but small enough to be able to work toward
agreement.8 A summary of participant numbers and stake-
holder groups in each meeting together with each DC
duration is shown in Table 1.
An impartial facilitator (J.B.C., study co-author)
guided the process interaction while refraining from con-
tributing to content, essentially helping the group in how
to think about the issues but not what to think,40,52 thus
pointing to an interactive model-building process in
which debate was encouraged and differences in opinion
were actively sought in an iterative manner. Where con-
sensus could not be reached, value judgments were
selected based on majority voting, representing a single
preference input for the whole group of participants and
the relevant parameter was then tested in sensitivity anal-
ysis (the Supplementary Appendix contains further infor-
mation about the decision conferencing process).
Compound overall value was obtained through the
application of the additive aggregation model. The AVF
was operationalized by adopting a typical simple addi-
tive aggregation approach, where the overall value V(.)
of an option a would be given by Eq. (2)27:
V að Þ=
Xm
i= 1
wivi(a) ð2Þ
where vi(a) is the partial value score of option a obtained
by the application of the value function of criterion i to the
performance of a in that criterion, wi is the weight of criter-
ion i, and m is the total number of criteria (attributes). This
function V(.)_ is effectively a multiattribute value function.11
A MACBETH (Measuring Attractiveness by a
Categorical-Based Evaluation Technique) protocol was
adopted as an approach to elicit value preferences, effec-
tively using qualitative judgments about the difference in
value between different pairs of performance levels.53,54
MACBETH is based on strong theoretical founda-
tions,55 and its usefulness as a decision support tool has
been shown through numerous applications for a variety
of real-world problems56,57 as part of which semantic
judgments are converted into a cardinal scale. We used
M-MACBETH,58 a decision support system based on
the MACBETH approach, to elicit value preferences of
DC participants and complete the MCDA model.
Following the DCs, additional deterministic sensitivity
analysis was conducted to address parameter uncertainty
on criteria weights, by systematically exploring changes on
baseline weights and their impact on the overall value rank-
ings of the compounds (the Supplementary Appendix con-
tains further information on MACBETH, M-MACBETH,
and the robustness analysis conducted).
Results
Final Value Trees
The attributes of the final NASH value tree in each coun-
try, as emerged following discussions with DC partici-
pants, are listed in Table 2. Schematic illustrations of the
final value trees emerging from each DC are shown in
Supplementary Appendix Figure A1.
Across the 3 study countries over the 2 rounds of
DCs, 14 to 19 attributes were included in the value tree,
as shown in Table 3. In terms of the different criteria
clusters’ composition, in round 1 the THE cluster com-
prised 9 to 10 attributes, followed by SAF (5 attributes)
and INN (2–4 attributes) clusters. In round 2, THE com-
prised 7 to 10 attributes, followed by SAF (5–9 attri-
butes) and INN (1 attribute) clusters. In round 2, the
value tree of each country consisted of the same or lower
number of attributes compared with round 1. In both
rounds of DCs, the largest number of criteria were allo-
cated under the THE cluster, followed by SAF and INN,
with the exception of the second round in Germany,
where more criteria were included in the SAF cluster, fol-
lowed by THE and INN.
A common feature of changes in the composition of
value trees across all 3 countries over the two rounds
was the non-inclusion of spillover effect criteria under
the INN cluster because they were considered to be non-
relevant for the scope of the exercise. Another common
feature as evident from the English and French DCs was
the non-inclusion of the SF-36 summary scores (physical
Table 1 Decision Conference Participant Numbers,
Stakeholder Groups, and Durations
HCP METH PAT Total
DC Duration,
days
Round 1
England 8 4 1 13 1.5
France 4 2 0 6 1.0
Germany 4 2 1 7 1.0
Round 2
England 5 4 1 10 1.5
France 6 4 10 1.5
Germany 2 2 1 5 1.5
Note: HCP, health care professional(s); METH, methodologists; PAT,
patient(s) and/or patient advocates.
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and mental component scores) as they were judged to be
non-clinically meaningful.
Criteria Weights
The relative weights of individual criteria across both
rounds are illustrated in Figure 1. In terms of the total
weights assigned across the different criteria clusters, the
THE cluster always obtained the highest rank, followed
by SAF and INN, with the exception of round 2 of the
German DC, in which the SAF cluster outranked THE.
The fact that the THE cluster always contributed to
more than 50% of the model’s total weight means that
an improvement from the worst to the best reference
Table 3 Number of Criteria Attributes and Their Relative Weights per Criteria Cluster across the 3 Countries
Criteria Clusters/
Countries
England France Germany
Criteria (n) Criteria Weights (%) Criteria (n) Criteria Weights (%) Criteria (n) Criteria Weights (%)
Round 1 (2017)
Therapeutic benefit 10 64.7 9 66.31 10 58.48
Safety profile 5 19.79 5 27.71 5 31.57
Innovation level 4 15.51 2 5.98 3 9.95
Total 19 100 16 100 18 100.0
Round 2 (2018)
Therapeutic benefit 8 59.84 10 61.01 7 35.96
Safety profile 5 28.37 5 37.6 9 62.28
Innovation level 1 11.79 1 1.39 1 1.74
Total 14 100 16 100 17 100.0
Figure 1 Relative weights of criteria across the 2 rounds of decision conferences. NASH RES, NASH Resolution; FIBROSIS,
fibrosis improvement; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; HbA1c, hemoglobin
A1c; WEIGHT, body weight; SYSTOL, systolic blood pressure; DIASTOL, diastolic blood pressure; ALT, alanine
aminotransferase; TRIGLY, triglycerides; GGT, gamma-glutamyl transferase; HOMA-IR, Homeostatic Model Assessment of
Insulin Resistance; SF-PHYS, SF-36 physical component score; SF-MENT, SF-36 mental component score; T-SAE, treatment-
related serious adverse events; O-SAE, overall serious adverse events; NAUSEA, nausea; NAU, VOM, DIA, nausea, vomiting,
and diarrhea; PRURI 1_2, pruritus grades 1 and 2; PRURI 2_3, pruritus grades 2 and 3; PRURI 3, pruritus grade 3; RENAL,
renal events; FATIGUE, fatigue; CARDIO, cardiovascular events; CONTRA, contraindications; DDI, drug-drug interactions;
PHASE 2, phase 2 indications; PHASE 3, phase 3 indications; MARKET, market authorized indications; DELI, delivery system
and posology.
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level in this cluster’s criteria would always be considered
more valuable than an improvement in the other criteria
clusters combined. Across countries, the relative weight
of the SAF cluster increased in round 2 compared with
round 1 to the detriment of the THE and INN clusters,
whose relative weights declined. In terms of individual
criteria, the number of highest-ranked criteria assigned a
relative weight of 10% or more was always observed to
be higher in the second compared with the first round of
DCs across all 3 countries. The relative weights of cri-
teria and their differences across countries reflect the
actual value preferences of the participants but are also
influenced by the number of criteria being considered in
each value tree.
In England, the THE cluster accounted for the highest
proportion of the model’s relative weight, followed by
SAF and INN; this result was consistent in both rounds.
Four criteria were assigned a relative weight of 10% or
more in round 1 (fibrosis improvement [19.8%], HbA1c
[13.4%], delivery system and posology [10.7%], body
weight [10.2%]), in contrast to 5 criteria in round 2
(fibrosis improvement [25.3%], NASH resolution [19.4%],
treatment-related serious adverse events [13.5%], pruritus
G1,2 [12.1%], delivery system and posology [11.8%]).
In France, across both rounds, the THE cluster
accounted for the highest proportion of the model’s rela-
tive weight, followed by SAF and INN. Three criteria
were assigned a relative weight of 10% or more in the
first round (NASH resolution [25.0%], fibrosis improve-
ment [24.5%], pruritus G2,3 [12%]) compared with 4 cri-
teria in the second round (fibrosis improvement [18.1%],
NASH resolution [14.9%], overall serious adverse events
[14.4%], nausea, vomiting, and diarrhea [11.1%]).
In Germany, there were some differences in the over-
all weight of clusters between rounds, such that the THE
cluster was outranked by the SAF cluster in the second
round in terms of their total weights, followed by INN
in third place. Although only a single criterion was asso-
ciated with a relative weight of 10% or more in round 1
(fibrosis improvement [17.0%]), a total of 5 criteria were
assigned a relative weight of 10% or more in round 2
(fibrosis improvement [18.3%], overall serious adverse
events [15.3%], NASH resolution [14.2%], cardiovascu-
lar adverse events [13.1%], nausea, vomiting, and diar-
rhea [10.2%]).
Of the 6 rounds, fibrosis improvement ranked first 5
times and second once, with a relative weight ranging
from 17.0% to 25.3%. NASH resolution appeared in the
top-3 for a total of 4 times, and serious adverse events
(treatment related or overall, depending on the country)
ranked second or third 4 times.
Overall Compound Rankings and Value
Composition
In terms of the compounds’ overall rankings, across the 3
countries and the 2 rounds of DCs, compound D was
always ranked first (overall weighted preference value
(WPV) score range: 67.4–90.6). With the exception of the
second round of the German DC, in which compound A
ranked second and compound C third (overall scores of
42.5 and 33.8, respectively), in all remaining rounds across
countries compound C ranked second and compound A
ranked third (overall score ranges: 33.8–63.3 and 37.0–46.3,
respectively). Compound B always ranked last (overall
score range: 24.7–38.2). The largest difference between the
first and second ranked compound was 48.1 points (D over
A in the second DC in Germany), whereas the smallest dif-
ference was 6 points (D over C in the first DC in England).
The overall WPV scores for all compounds across the
study countries and the 2 DC rounds are shown in Table
4. Stacked bar plots of the compounds’ overall WPV
scores across the 3 countries over the 2 rounds of DCs
are shown in Figures 2 to 4, with absolute value contri-
butions of each criterion. It should be clear that the over-
all WPV score of each option depends on the criteria
included in the value model, the shape of the value
Table 4 Overall Weighted Preference Value (WPV) Scores of the Compounds across the 3 Countries over the 2 Rounds
of Decision Conferencesa
England France Germany
2017 2018 2017 2018 2017 2018
Compound A 42.03 40.93 37.73 37.03 46.33 42.52
Compound B 31.44 27.84 24.74 31.14 38.24 30.34
Compound C 61.42 63.32 62.22 60.82 57.92 33.83
Compound D 67.41 78.51 74.21 70.01 70.01 90.61
aSuperscript numerals indicate the compound ranking: 1 = first ranked; 2 = second ranked; 3 = third ranked; 4 = fourth ranked.
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Figure 2 Stacked bar plots of compounds’ overall weighted preference value scores over the 2 rounds of decision conferences in
England. (a) Round 1. (b) round 2.
Figure 3 Stacked bar plots of compounds’ overall weighted preference value scores over the 2 rounds of decision conferences in
France. (a) Round 1. (b) Round 2.
Figure 4 Stacked bar plots of compounds’ overall weighted preference value scores over the 2 rounds of decision conferences in
Germany. (a) Round 1. (b) Round 2.
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functions that influence the value scores, and the criteria
weights that are elicited using the 2 reference levels.
In the English and French DCs, the largest proportion
of the leading compound’s value contribution (compound
D) was always due to its performance on the THE clus-
ter, followed by the SAF and INN clusters. By contrast,
in the German DC, the largest proportion of compound’s
D value was accounted for by the SAF cluster in both
rounds, followed by the THE and INN clusters. In terms
of individual criteria, across all 3 countries and over both
rounds, fibrosis improvement was always the most influ-
ential value dimension on compound’s D overall value
composition, contributing the greatest value score.
The sensitivity and robustness analyses demonstrated
that treatment rankings are robust to the relative criteria
weights across the different settings. The only case in
which a change of less than 100% of a criterion’s weight
could affect the compound ranking was in the first DC
round in England and France, in which a 29% reduction
in fibrosis improvement (from 19.8% to 14.0%) and a
77% increase in NASH resolution (from 25% to 44.2%)
would be adequate for compound C to become better
ranked than compound D.
Discussion
This two-round, cross-country exercise demonstrated the
application of a recently developed MCDA methodologi-
cal process and value framework25,27 for a set of alterna-
tive compounds under clinical development versus a HPP
in the context of early HTA. In terms of design, implemen-
tation and review of the analysis, the process adopted was
in alignment with good practice guidelines on the use of
MCDA in health care decisions.23,24
Compound Ranking and Value Preferences
Based on the MCDA model used, the set of evaluation
criteria considered, and the respective performance of the
compounds used, we found that the ranking of the com-
pounds was virtually identical across the study countries
and both DC rounds. Compound D always ranked first
based on DC participants’ overall WPV scores, followed
by compounds C, A, and B, with the exception of the sec-
ond DC in Germany, where compound A ranked higher
than compound C.
In terms of the various value reflections, with the
exception of the second German DC, the THE cluster
had the highest relative importance for participants
across all 3 countries (59%–66% of model weight),
always followed by the SAF (20%–38%) and the INN
clusters (1%–16%). With the exception of the second
German DC, the SAF cluster outranked the THE cluster
with 62% versus 36%.
Fibrosis was the most important criterion across
countries and DC rounds, having the highest relative
weight in most cases, with the exception of the French
DC (round 1 only), where it was assigned the second
highest weight but still very close to the top-ranked cri-
terion. In France, the 2 histologic endpoints played the
most important role to stakeholders in both rounds; this
partly explains why the THE cluster produced the high-
est relative weight across all 3 countries.
Some differences were recorded between rounds and
the criteria accounting for at least 50% of the model
weight in each case. In the English DCs, for at least 50%
of the model’s weight to be accounted for, weights of the
3 leading criteria had to be included, adding up to 58%
in the second round (the 2 histologic endpoints and
treatment-related serious adverse events). By contrast,
the 4 highest ranking criteria in the first round (fibrosis
improvement, HbA1c, delivery system and posology,
and body weight) accounted for 54% of the model’s
weight. In the French DCs, for at least half the model’s
weight to be captured, the weights of the four highest
ranking criteria in the second round had to be included,
adding up to 59% (the 2 histologic endpoints, overall
serious adverse events and nausea, vomiting, and diar-
rhea); by contrast, the top 3 criteria in the first round
accounted for 61% of total model weight (the 2 histolo-
gic endpoints and pruritus G2,3). In the German DCs,
for at least half the importance of the model’s weight to
be captured, in the second round the weights of the 4
highest ranking criteria had to be included, adding up to
61% (the 2 histologic endpoints, overall serious adverse
events and cardiovascular adverse events). In compari-
son, the 5 highest ranking criteria in the first round
added up to 51% (fibrosis improvement, treatment-
related serious adverse events, pruritus G2,3, nausea and
delivery system and posology).
Overall, nearly identical results were observed across
countries and rounds in terms of compound rankings.
Understandably, the direct comparison of overall value
scores between options requires identical value models,
comprising the same criteria sets, weights, and value func-
tions. The ranking comparisons made in this study using
ordinal scales reflect these restrictions. Nevertheless,
when trying to interpret differences in results between
countries, it could be argued that any disparities might be
due to either ‘‘real’’ country differences relating to the
consideration of different fundamental objectives, priori-
ties, and preferences (as reflected through differences in
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criteria inclusion, relative weights assignment, and scores
elicitation), or differences relating to individual partici-
pants. This was indirectly addressed through the extensive
sensitivity analysis conducted, aiming to reduce para-
meter and, by extension, intracountry uncertainty, but
also through the further insights generated in the second
round of DCs, which practically validated the results of
the first round.
Limitations
One of the study limitations is the lack of relative effect
estimates as part of clinical evidence and the use of their
absolute effects from different clinical trials with the
assumption that they can be compared directly. Given
the absence of head-to-head clinical trials directly com-
paring the compounds of interest, the small number of
clinical trials available and their early phase, absolute
effects from the respective single randomized clinical
trials of the alternative compounds were used. If more
clinical studies become available, an indirect treatment
comparison could be conducted first using a common
comparator to estimate the relative effects of 2 treat-
ments versus the comparator, or a network meta-analysis
combining both direct and indirect evidence available
through a mixed treatment comparison. Although the
placebo range was disclosed to participants during the
workshops, the incremental performance difference from
placebo would be needed to better understand the associ-
ated value. In real-world evaluations aiming to inform
decision making, evidence synthesis would be required to
take place together with evidence collection as part of
the model-building phase.
A second limitation relates to the clinical trials used
as the source of evidence. Only data from a single, phase
2, randomized clinical trial per compound was used with
relatively small sample sizes (number of subjects ran-
domly assigned in either arm ranging from 26–142
patients).
Third, the studies used had different populations (dis-
ease stage), different trial durations, and one did not
meet its primary endpoint, all of which have implications
in terms of their comparability and perceived efficacy.
Differences in the definitions of histologic endpoints
across studies were assumed to be comparable, consider-
ing that a consensus across NASH primary outcome def-
initions is lacking. Given the uncertainty around
treatment effects, participants were instructed to assume
that they corresponded to a specific sample size of
patients, chosen based on the largest number of patients
in a single active arm evident across the studies (N =
142), which helped participants to provide a value judg-
ment across the clinical attributes.
Finally, in relation to the participatory approach
adopted, not all DCs were of the same size or had the
same composition of experts, particularly the second DC
in Germany (5 participants), which may have contribu-
ted to a different overall compound ranking order.
Lessons Learned
Despite the limitations, this study demonstrated consis-
tency of MCDA results following 2 rounds of preference
elicitation via DCs with different participants in 3 set-
tings, suggesting that value preferences and their differ-
ences between countries are fairly reliable.
One contribution of this study relates to the value
attribution of NASH compounds in different countries
as reflected through the key drivers of their overall
scores. The 2 histologic endpoints of fibrosis improve-
ment and NASH resolution had a clear influence in this
context. Regarding differences in the acceptability of the
evaluation criteria considered, the German experience
(and, to a lesser degree, the French experience) suggests
that it is paramount to submit evidence on clinically
meaningful outcomes relating to mortality, morbidity,
and quality of life. Alternatively, if surrogate endpoints
are used, they should be accompanied with a clear impact
on relevant clinically meaningful outcomes or demon-
strate minimum clinically important differences. This
could be informed by randomized prospective interven-
tional studies or by focusing on the magnitude of the
studies rather than follow-up duration.
A number of insights relating to the usefulness of
MCDA in early HTA have been generated. In terms of
the phase of clinical development, it became obvious that
there will be a trade-off between data availability and
prospects of influencing drug development. Regarding
the preference for data on clinical versus surrogate end-
points, this seems to be universally true, but surrogates
can probably be accepted if they are validated and can
predict the clinical endpoint. It is recommended to pro-
vide correlations of surrogates with outcomes and/or
clinically meaningful thresholds.
A critical issue observed across the different country
settings was the current clinical debate given the lack of a
clear disease definition, including the challenges around
disease diagnosis and identification of patients in greater
need. The debate around clinically meaningful outcomes
was indicative in that context, with most clinical studies
using histologic endpoints as surrogate markers. This
suggests that a better understanding of the disease
together with the development of improved clinical
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guidelines could potentially benefit the elevation of
NASH in the national policy agendas of decision and
policy makers.
In terms of methodological contribution, the analyti-
cal objectives in early HTA contexts should always be
clearly defined (e.g., evaluation of current product pro-
files vs. design of future phase 3 trials) to facilitate pre-
ference elicitation as part of DCs or other participatory
processes. With regard to improvements around evidence
synthesis and summary, assuming the use of nonsynthe-
sized clinical evidence and the existence of a common
comparator (such as placebo arms), the use of perfor-
mance levels compared with the comparator (e.g., incre-
mental placebo differences) should be explored. Using
performance levels, it could be easier for participants to
comprehend the significance of any relevant treatment
effects. However, it should be considered whether this
might have an influence on the definition and interpreta-
tion of the reference levels, as an ‘‘incremental’’ treat-
ment effect might also have to be present across other
non-clinical criteria for a more homogeneous and easier
interpretation of the results.
Importantly, for the use of non disease-specific clini-
cally meaningful outcomes, it might be useful to derive
clinically meaningful thresholds or correlations that
could inform the elicitation of value judgments and pre-
ferences, for example, minimally clinically important dif-
ference for PRO instruments.
Finally, DCs should be conducted over a 2-day period
to allow sufficient time for discussion and evidence synth-
esis tasks, the greatest trade-off being the challenge in
recruiting adequate numbers of participants. Venues
should be in alignment with DC good practice guide-
lines with U-shaped seating for direct eye contact and 2
projector screens (one with the value tree, the other
with the options performance data). The pool of poten-
tial experts to contact to secure adequate DC partici-
pants should not be underestimated, particularly in
follow-on rounds, as more than 125 experts were con-
tacted to secure 25 in the second round.
Conclusion
In this study, we explored the application of the Advance
Value Framework in the context of early HTA for
NASH compounds in 3 EU countries and tested the con-
sistency of results by conducting 2 rounds of preference
elicitation via decision conferencing. The use of MCDA
proved to be promising for early HTA while illustrating
high consistency in results across countries and between
study rounds. The complexity of NASH management,
given the existence of patients with multiple comorbid-
ities and clinical endpoints, enables MCDA to act as a
transparent and potentially consistent approach for evalu-
ating compounds in clinical development before market
entry. The results can be used to ensure that relevant and
important endpoints are included in upcoming clinical
studies and to identify potential discrepancies across HTA
bodies in terms of value assessment requirements. Ongoing
and future research could validate and possibly supple-
ment insights provided regarding differences in value pre-
ferences in different settings, whether for NASH or HTA
appraisals more generally.
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